Brain cancer

Brain tumors are among the most devastating forms of cancer, with a poor 5-year survival rate of only 32%. Among these, glioblastoma is the most aggressive type. Despite intensive multimodal treatment—including surgery, chemotherapy, and radiotherapy—patients face a median overall survival of just 14–16 months after diagnosis. Tumor progression is inevitable, and there are no well-defined treatment options once the tumor recurs.

Given this dire prognosis and the lack of effective therapies, the 4Brain lab is focused on developing novel and more effective treatment strategies for glioblastoma. In parallel, we are creating advanced methods to realistically model brain tumors in the laboratory and in animal models, allowing us to test new therapies under conditions that closely reflect the situation in patients.

Discover the different glioblastoma research lines at 4Brain.

Meet our brain cancer researchers at 4Brain.

Professor Robrecht Raedt, PhD, is leading the preclinical 4Brain research lab, with a main focus on new treatment techniques as a treatment for various neuropsychiatric disorders (epilepsy, stroke, multiple sclerosis, glioblastoma).

Publications

Professor Paul Boon, MD, PhD, is neuroloog aan het Universitair Ziekenhuis Gent. Hij leidt een multidisciplinair onderzoeksteam dat zich richt op het ontrafelen van complexe hersenmechanismen om nieuwe therapieën te ontwikkelen voor de meest voorkomende neurologische aandoeningen. Het research4Brain onderzoeksteam wil een verschil maken voor de steeds toenemende groep mensen die met een hersenaandoeningen leven.

Consent

Brain cancer

Discover the different glioblastoma research lines at 4Brain.

Drug Repurposing

Motility trapping

BBB opening /radionuclides

Meet our brain cancer researchers at 4Brain.

Kristl Vonck

Robrecht Raedt

Paul Boon